These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB).
    Author: Epstein AL, Haag-Molkenteller C.
    Journal: Cell; 2023 Aug 17; 186(17):3523-3523.e1. PubMed ID: 37595560.
    Abstract:
    The FDA has recently approved Krystal biotech's beremagene geperpavec (B-VEC, Vyjuvek) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients. This represents a giant step, not only toward the treatment of this devastating disease, but also for the whole field of non-replicative (nr) recombinant HSV-1 vectors for gene therapy. To view this Bench to Bedside, open or download the PDF.
    [Abstract] [Full Text] [Related] [New Search]